Spyre Therapeutics (SYRE) traded higher as risk appetite returned following two major catalysts this week: upbeat initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial for SPY001 in moderate-to-severely active ulcerative colitis, and the clearing of a large financing overhang after the company priced an upsized public offering at $62 per share. The combination of perceived clinical momentum plus improved balance-sheet visibility is supporting incremental buying despite dilution concerns. (sec.gov)

In the April 13, 2026 8-K, Spyre disclosed that SPY001 achieved the primary endpoint in SKYLINE Part A, with a statistically significant reduction in Robarts Histopathology Index (RHI) score (reported as -9.2, p<0.0001). Spyre also reported Week 12 clinical remission of 40% and endoscopic improvement of 51%, alongside tolerability described as consistent with the α4β7 class, with 6 of 43 subjects reporting treatment-emergent adverse events during induction and no drug-related adverse events reported. (sec.gov)

Spyre priced an upsized underwritten public offering of 6.5 million shares at $62, implying gross proceeds of roughly $403 million, with closing expected on or about April 16, 2026 subject to customary conditions. Stocks that gap up on clinical news frequently see choppy trading after a follow-on deal; today’s move suggests some investors are treating the raise as de-risking—funding next trials and combinations—rather than purely dilutive supply. (sahmcapital.com)

Spyre said recruitment for Part A is closed and enrollment is open for Part B, which includes monotherapy cohorts (SPY001, SPY002, SPY003) and combination cohorts versus a shared placebo. The company guided that proof-of-concept induction data for remaining Part A cohorts are expected mid-2026 for SPY002 and in Q3 2026 for SPY003, with Part B induction data for all cohorts on track for 2027—setting up the next potential catalysts that could keep the stock reactive around readouts and trial updates. (sec.gov)